WallStreetZenWallStreetZen

NASDAQ: NBIX
Neurocrine Biosciences Inc Stock

$134.66-1.37 (-1.01%)
Updated Feb 28, 2024
NBIX Price
$134.66
Fair Value Price
N/A
Market Cap
$13.40B
52 Week Low
$89.04
52 Week High
$143.35
P/E
52.6x
P/B
6x
P/S
6.82x
PEG
0.97x
Dividend Yield
N/A
Revenue
$1.89B
Earnings
$249.70M
Gross Margin
97.9%
Operating Margin
17.84%
Profit Margin
13.2%
Debt to Equity
0.46
Operating Cash Flow
$390M
Beta
0.67
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

NBIX Overview

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.

Zen Score

Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NBIX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

NBIX ($134.66) is trading above its intrinsic value of $62.88, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NBIX is poor value based on its earnings relative to its share price (52.6x), compared to the US market average (35.52x)
P/E vs Market Valuation
NBIX is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more NBIX due diligence checks available for Premium users.

Be the first to know about important NBIX news, forecast changes, insider trades & much more!

NBIX News

Valuation

NBIX fair value

Fair Value of NBIX stock based on Discounted Cash Flow (DCF)
Price
$134.66
Fair Value
$141.18
Undervalued by
4.62%
NBIX ($134.66) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

NBIX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
52.6x
Industry
46.2x
Market
35.52x
NBIX is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
NBIX is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation

NBIX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
6x
Industry
2.27x
NBIX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

NBIX price to earnings growth (PEG)

For valuing profitable companies with growth potential
NBIX is good value based... subscribe to Premium to read more.
PEG Value Valuation

NBIX's financial health

Profit margin

Revenue
$515.2M
Net Income
$147.7M
Profit Margin
28.7%
NBIX's Earnings (EBIT) of $336.70M... subscribe to Premium to read more.
Interest Coverage Financials
NBIX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$3.3B
Liabilities
$1.0B
Debt to equity
0.46
NBIX's short-term assets ($1.61B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NBIX's short-term assets ($1.61B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NBIX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NBIX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$123.5M
Investing
-$201.8M
Financing
$35.4M
NBIX's operating cash flow ($389.90M)... subscribe to Premium to read more.
Debt Coverage Financials

NBIX vs Pharmaceutical Stocks

TickerMarket Cap1d %P/EP/B
NBIX$13.40B-1.01%52.60x6.00x
RDY$12.84B+0.34%N/A4.57x
TEVA$14.68B-1.58%-26.18x1.96x
VTRS$14.74B-7.11%8.09x0.71x
CTLT$10.47B-0.45%-8.06x2.84x

Neurocrine Biosciences Stock FAQ

What is Neurocrine Biosciences's quote symbol?

(NASDAQ: NBIX) Neurocrine Biosciences trades on the NASDAQ under the ticker symbol NBIX. Neurocrine Biosciences stock quotes can also be displayed as NASDAQ: NBIX.

If you're new to stock investing, here's how to buy Neurocrine Biosciences stock.

What is the 52 week high and low for Neurocrine Biosciences (NASDAQ: NBIX)?

(NASDAQ: NBIX) Neurocrine Biosciences's 52-week high was $143.35, and its 52-week low was $89.04. It is currently -6.06% from its 52-week high and 51.24% from its 52-week low.

How much is Neurocrine Biosciences stock worth today?

(NASDAQ: NBIX) Neurocrine Biosciences currently has 99,507,490 outstanding shares. With Neurocrine Biosciences stock trading at $134.66 per share, the total value of Neurocrine Biosciences stock (market capitalization) is $13.40B.

Neurocrine Biosciences stock was originally listed at a price of $7.88 in Dec 31, 1997. If you had invested in Neurocrine Biosciences stock at $7.88, your return over the last 26 years would have been 1,609.97%, for an annualized return of 11.54% (not including any dividends or dividend reinvestments).

How much is Neurocrine Biosciences's stock price per share?

(NASDAQ: NBIX) Neurocrine Biosciences stock price per share is $134.66 today (as of Feb 28, 2024).

What is Neurocrine Biosciences's Market Cap?

(NASDAQ: NBIX) Neurocrine Biosciences's market cap is $13.40B, as of Feb 29, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Neurocrine Biosciences's market cap is calculated by multiplying NBIX's current stock price of $134.66 by NBIX's total outstanding shares of 99,507,490.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.